Curevac Efficacy Data. Share this article now. Currently however the results fall short of the 50 efficacy threshold regulators have established for coronavirus vaccines a significant setback for CureVac and a perplexing contrast to the data supporting vaccines from Moderna and partners Pfizer and BioNTech which rely on similar messenger RNA technology.
The HERALD study was conducted on about 40000 volunteers in ten. Eighty-three of those cases were among participants who had received two shots of CureVacs vaccine while 145 were in volunteers given placebo. CureVacs latest data come from 228 cases of COVID-19 reported in its Phase 2b3 study which enrolled approximately 40000 volunteers in Latin America and Europe.
June 30 Reuters - CureVac 5CVDE said its COVID-19 vaccine was 48 effective in the final analysis of its pivotal mass trial.
The principle of CureVacs proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Company Update - Unique pivotal study conducted in 10 countries in fast changing variant environment. An earlier version of this article misstated the efficacy of the CureVac vaccine. Share this article now.
